Protocol No. | UW24147 CHS-388-202 |
||
---|---|---|---|
Principal Investigator | Kratz, Jeremy | ||
Phase | II | ||
Age Group | Adult | ||
ClinicalTrials.Gov | NCT06679985 (Click to jump to clinicaltrials.gov) | ||
Management Group(s) | Gastrointestinal | ||
Title
Description
Objective
Treatment
Drug: Casdozokitug
Key Eligibility
Key Inclusion Criteria:
Unresectable locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic participants. Disease that is not amenable to curative surgical and/or locoregional therapies or progressive disease (PD) after surgical and/or locoregional therapies. >/= 1 measurable lesion (per RECIST v1.1) that is untreated.
Applicable Disease Sites
Participating Institutions
|